Vorinostat

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 28.11.2021

Dieser Artikel auf Deutsch

Synonym(s)

Suberoylanilide hydroxamic acid inhibitor

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Oral histone deacetylase inhibitor approved by the US Food and Drug Administration in October 2006 for the treatment of patients with refractory advanced cutaneous T-cell lymphoma.

Pharmacodynamics (Effect)This section has been translated automatically.

The effect is based on an inhibition of histone deacetylase; see also histones below). In vitro studies have shown that vorinostat inhibits histone deacetylase (HDAC) even at low concentrations (nanomolar). It is assumed that some cancer cells have an excess of histone deacetylases and thus suppress further cellular processes that regulate apoptosis, among other things. Vorinostat inhibits the effect of this HDAC. It is hoped that this will reduce the activity of the cancer cells; the exact mechanism is currently not fully characterised.

IndicationThis section has been translated automatically.

Cutaneous T-cell lymphoma ( off-label use).

Pregnancy/nursing periodThis section has been translated automatically.

No use during pregnancy and lactation due to lack of data.

Dosage and method of useThis section has been translated automatically.

once/day 400 mg/day p.o. (together with a meal).

Undesirable effectsThis section has been translated automatically.

Described are gastrointestinal (e.g. diarrhoea, stomach complaints), hematological (e.g. anemia, thrombocytopenia), thrombembolic (e.g. pulmonary embolus), cardiac (e.g. QT prolongation) events, fever, anorexia, taste disorders and hyperglycaemia.

InteractionsThis section has been translated automatically.

  • Prolongation of prothrombin time and INR with simultaneous administration of coumarins.
  • Severe thrombocytopenia and gastrointestinal haemorrhage when administered simultaneously with other histone deacetylase inhibitors (e.g. valproic acid).

ContraindicationThis section has been translated automatically.

Insufficient data in children and patients with liver and kidney diseases.

PreparationsThis section has been translated automatically.

Zolinza (Merck)

Note(s)This section has been translated automatically.

Recent studies have evaluated the humanized CCR4 monoclonal antibody, mogamulizumab, in relapsed/refractory MF and SS, showing a significant benefit in progression-free survival (PFS). In August 2018, mogamulizumab was approved by the FDA for the treatment of patients with relapsed/refractory MF/SS who have failed at least one treatment. The approval was based on the Phase III MAVORIC trial, which compared mogamulizumab to vorinostat, an FDA-approved drug for this indication, in 372 patients. In this study, mogamulizumab was found to have superior PFS with a median of 7.7 months compared to 3.1 months in the vorinostat group, with a hazard ratio of 0.53, p<0.001 (Kim YH et al. 2018).

PatientinformationThis section has been translated automatically.

Make sure that you drink a sufficient amount of water (at least 2 litres/day)!

LiteratureThis section has been translated automatically.

  1. Grant S et al (2007) Vorinostat. Nat Rev Drug Discov 6: 21-22

  2. Kim YH et al. (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol19:1192-1204.

Authors

Last updated on: 28.11.2021

Author: Prof. Dr. med. Peter Altmeyer